CLYM:NASDAQ, Climb Bio, Inc.

CLYM stock overview

Climb Bio, Inc. (CLYM:NASDAQ) closed at $8.81 on October 26, 2026, down 13.54% on the day. The stock trades 51.9% below its 52-week high of $18.33 and 438.8% above its 52-week low of $1.64. Over the past year, it gained 319.5%. Climb Bio, Inc. is part of the Health Care sector.

Key figures

Price: $8.81
Day change: -13.54%
Volume: 3,381,116
Average volume: 1,376,695
Market cap: 506M+
52-week range: $1.64 – $18.33
50-day average: $13.18
200-day average: $10.27

Price action over the past year

In 252 trading sessions since October 24, 2025, CLYM closed higher on 131 days (52%). Its best day was December 12, 2025 (+30.43%) and its worst was October 26, 2026 (-13.54%). The stock moved 10% or more in a single session 19 times.

Recent signals

Oct 26, 2026: Down 27.3% over 90 days, from $12.11 (Dips & Crashes scanner)
Oct 26, 2026: Hit a new 6-Month Low of $8.81 (New Highs/Lows scanner)
Oct 24, 2026: News catalyst: Biotech (News Catalysts scanner)
Aug 25, 2026: Spiked to $18.33 on 1M+ shares (Spikes scanner)

CLYM news

About Climb Bio, Inc.

Eliem Therapeutics Inc is a clinical-stage biotechnology company. It is focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems.

Similar stocks

Find more stocks like CLYM with the Spikes, Gaps, Breakouts and Performance Tracker scanners.

Based on end-of-day data. For information only, not investment advice.